
Ruijin Hospital
Shanghai, China
Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, was founded in 1907 and has grown into a leading Class 3A academic medical centre with close to 2,800 beds across three campuses in Shanghai. It is internationally recognised in haematology: physician-scientists at Ruijin — including Wang Zhenyi, Chen Zhu, and Chen Saijuan — developed the combined all-trans retinoic acid (ATRA) and arsenic trioxide therapy for acute promyelocytic leukaemia, raising five-year survival from roughly 10% to over 97% and reshaping leukaemia treatment worldwide. The hospital completed a DNV DIAS international accreditation audit in 2025, recognised by insurers in more than 130 countries, and also maintains strong programmes in endocrinology and minimally invasive gastrointestinal surgery.


